Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Camostat mesylate (HB3595)
Description:Serine protease inhibitor. Inhibits TMPRSS2 and partially blocks SARS-Cov2 entry in vitro.
Purity:>98%
Cyclosporin A (HB0220)
Description:Potent calcineurin inhibitor. Inhibits MPTP opening.
Purity:>99%
Disulfiram (HB1119)
Description:Reversibly stimulates SERCA Ca2+-ATPase. V-ATPase inhibitor.
Purity:>97%
Imatinib mesylate (HB1943)
Description:Tyrosine kinase inhibitor that targets BCR‑ABL, c‑KIT, and PDGFR kinases
Purity:>98%